Excitement among patients and researchers as custom-built jabs enter phase 3 trial

Doctors have begun trialling in hundreds of patients the world’s first personalised mRNA cancer vaccine for melanoma, as experts hailed its “gamechanging” potential to permanently cure cancer.

Melanoma affects about 132,000 people a year globally and is the biggest skin cancer killer. Currently, surgery is the main treatment although radiotherapy, medicines and chemotherapy are also sometimes used.

Now experts are testing new jabs that are custom-built for each patient and tell their body to hunt down cancer cells to prevent the disease ever coming back.

A phase 2 trial found the vaccines dramatically reduced the risk of the cancer returning in melanoma patients. Now a final, phase 3, trial has been launched and is being led by University College London Hospitals NHS Foundation Trust (UCLH).

Dr Heather Shaw, the national coordinating investigator for the trial, said the jabs had the potential to cure people with melanoma and are being tested in other cancers, including lung, bladder and kidney.

  • AutoTL;DR@lemmings.worldB
    link
    fedilink
    English
    arrow-up
    2
    ·
    6 months ago

    This is the best summary I could come up with:


    Now experts are testing new jabs that are custom-built for each patient and tell their body to hunt down cancer cells to prevent the disease ever coming back.

    A phase 2 trial found the vaccines dramatically reduced the risk of the cancer returning in melanoma patients.

    Now a final, phase 3, trial has been launched and is being led by University College London Hospitals NHS Foundation Trust (UCLH).

    Dr Heather Shaw, the national coordinating investigator for the trial, said the jabs had the potential to cure people with melanoma and are being tested in other cancers, including lung, bladder and kidney.

    It is designed to trigger the immune system so it can fight back against a patient’s specific type of cancer and tumour.

    The jab carries coding for up to 34 neoantigens and activates an anti-tumour immune response based on the unique mutations in a patient’s cancer.


    The original article contains 604 words, the summary contains 147 words. Saved 76%. I’m a bot and I’m open source!